Prothena (PRTA) stock price today was up over 87%. Prothena is a late-stage clinical company engaged in the protein dysregulation. Their pipeline includes Parkinson's disease and Alzheimer's therapies. The PRTA stock was upgraded following positive data from Biogen (BIIB). George Tsilis weighs in on the BOFA analyst note that stated Prothena trial result is a big milestone in the treatment of Alzheimer's disease.
Market On Close
28 Sep 2022
SHARE
Next Gen Investing
05 Jul 2023
Trading 360
10 Jul 2023
Market On Close
07 Jul 2023
Morning Trade Live
15 Sep 2023
Morning Trade Live
08 Aug 2023
Morning Trade Live
10 Jul 2023